Article Information
History
- October 9, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Abigail E. Schiff, MD PhD1,4,
- Xiaosong Wang, MS2,
- Naomi J. Patel, MD3,4,
- Yumeko Kawano, MD2,4,
- Emily N. Kowalski, BS2,
- Claire E. Cook, MPH3,5,
- Kathleen M.M. Vanni, BA2,
- Grace Qian, BA&Sc2,
- Katarina J. Bade, BS2,
- Alene A. Saavedra, BA2,
- Shruthi Srivatsan, BS3,
- Zachary K. Williams, BS3,
- Rathnam K. Venkat, BS6,
- Zachary S. Wallace, MD MSc3,4,5,* and
- Jeffrey A. Sparks, MD MMSc2,4,†,*
- 1Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA (60 Fenwood Road, Boston, MA, 02115)
- 2Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA (60 Fenwood Road, Boston, MA, 02115)
- 3Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA (Rheumatology Associates, 55 Fruit Street, Boston, MA, 02114)
- 4Harvard Medical School, Boston, MA
- 5Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA (The Mongan Institute, 100 Cambridge Street, Suite 1600, Boston, MA, 02114)
- 6Tufts University School of Medicine, Boston, MA, USA (145 Harrison Ave, Boston, MA 02111)
- ↵†Corresponding author,
Jeffrey A. Sparks MD MMSc, Division of Rheumatology, Inflammation, and Immunity Brigham and Women’s Hospital, 60 Fenwood Road, Suite 6016U Boston, MA 02115, Phone: 617-525-1040, Fax: 617-732-5766, jsparks{at}bwh.harvard.edu @jeffsparks
↵* Contributed equally (co-senior authors)
Posted October 09, 2023.
Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort study
